London, UK (PRWEB) July 17, 2015
How are perceived application values of personalised medicine ranked by physicians in EU-5? How do EU-5 physicians rank the major potential advantages of personalised medicine for patients and physicians? What are EU-5 physician opinions on today’s use of personalised medicine to treat all cancer types, comprising blood and solid tumours? How do the physicians rank challenges related to access and data? In case access and data challenges were minimal – what share of EU-5 physicians would prescribe personalised medicinal products? What key factors, according to EU-5 physicians, enable efficient use of personalised medicine, currently and in future? Answers to these burning questions and a lot more can be found in the report.
In-demand research study “Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)” drawn up by FirstWord is now available at MarketPublishers.com.
Title: Personalised Medicines in Oncology: Assessing Key Drivers and Challenges at the Physician Level (EU5)
Published: May, 2015
Price: US$ 6,900.00
The research study presents unique insights from the 150 treating oncologists in EU-5 on the perceived benefits and value of personalised medicine and also on the key opportunities and challenges associated with the implementation.
Reasons to Buy:
- Gain true insights into the EU5 oncologists’ awareness of personalised medicine, their influence on patient care and the value of personalised medicines clinical outcomes.
- Opinions on the promise and crucial benefits of personalised medicine, and major issues pertaining to how personalised medicine can ensure access to novel therapies.
- EU5 oncologists’ views on how personalised medicine will be used in the offing, as well as on the key barriers that are expected to slow down adoption rates.
More in-demand reports by the publisher can be found at FirstWord page.